Oct. 14 at 1:33 AM
The attachment compares
$SNDX market cap as a multiple of FY2028 analyst consensus & cumulative 5-year analyst estimates to peer comm'l-stage non-oncology focused bios. Note analysts forecast SNDX to generate more revenues than most of these non-oncology focused peers with much higher valuations. Is SNDX's valuation being held back by a 10/25/25 PDUFA?
The original intent of this post was to focus on the SNDX valuation disconnect with its non-oncology peers but we also follow
$FOLD because FOLD trades at a very low multiple of projected revenues. In FOLD's case, we believe the disconnect is due to a private pharma's threat to produce a generic Galafold. Galafold is supposedly patented thru FY38. Its patents have been challenged before by TEVA to no avail. The FOLD case went to court very recently. Should FOLD prevail perhaps its valuation will catch up with its peers?
$HROW $BCRX ?
We did exclude some SNDX non-oncology peers like SRPT HRMY &
$XERS for various reasons
